Design Therapeutics vs Sionna Therapeutics
DSGN and SION side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DSGN and SION compare
Design Therapeutics is the larger company, worth 4.4 times as much as Sionna Therapeutics ($621M against $141M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DSGN | SION |
|---|---|---|
| Size and price | ||
| Market cap | $621M | $141M |
| Share price | $9.92 | $3.12 |
| Change, 1 year | 40.5% | −91.3% |
| Change, 5 years | −44.2% | – |
| Beta (5Y) | 1.90 | 1.88 |
| Employees | 54 | 59 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.1× | 0.6× (better) |
| FCF yield | −8.9% (better) | −56.4% |
| Profitability | ||
| Return on equity | −34.1% (better) | −39.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 18.86 (better) | 13.92 |
| Altman Z-score | 25.79 (better) | 1.34 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 69.2% | 107% |
| Held by insiders | 21.2% | 50.1% |
| Insider net buying, 12 months | – | −$135M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 12.8% | 18.7% |
Go deeper
- DSGN stock overview
- DSGN income statement
- DSGN valuation and score
- SION stock overview
- SION income statement
- SION valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.